Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.46 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL714527 | 1.00 | MAPT (0.59) | MAPTGAAESR2SLC18A3SRD5A1 | |
| SCHEMBL714528 | 1.00 | MAPT (0.59) | MAPTGAAESR2SLC18A3SRD5A1 | |
| Ethylene SCHEMBL27953915 | 0.96 | MAPT (0.55) | MAPTGAAESR2SLC18A3SRD5A1 | |
| Hydrochloric Acid SCHEMBL9482313 | 0.96 | MAPT (0.55) | MAPTGAAESR2SLC18A3SRD5A1 | |
| SCHEMBL2312546 | 0.94 | MAPT (0.57) | MAPTGAAESR2SLC18A3SRD5A1 | |
| SCHEMBL18980773 | 0.94 | MAPT (0.57) | MAPTGAAESR2SLC18A3SRD5A1 | |
| SCHEMBL31252385 | 0.92 | MAPT (0.55) | MAPTGAAESR2SLC18A3SRD5A1 | |
| SCHEMBL29683554 | 0.92 | MAPT (0.55) | MAPTGAAESR2SLC18A3SRD5A1 | |
| SCHEMBL3446977 | 0.92 | MAPT (0.55) | MAPTGAAESR2SLC18A3SRD5A1 | |
| SCHEMBL19524597 | 0.91 | MAPT (0.50) | MAPTGAAESR2SLC18A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464861-B2 | Asymmetric addition reactions | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-11-05 | — | — | US | disclosed |
| US-10118169-B2 | Chiral ligand-based metal-organic frameworks for broad-scope asymmetric catalysis | THE UNIVERSITY OF CHICAGO (US) | 2018-11-06 | — | — | US | disclosed |
| EP-2816040-B1 | Process for the production of CCR2 receptor antagonists and intermediates thereof | CENTREXION THERAPEUTICS CORP (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20170173572-A1 | CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-22 | — | — | US | disclosed |
| US-20170173572-A1 | CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-22 | — | — | US | disclosed |
| US-20170173572-A1 | CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-22 | — | — | US | disclosed |
| CN-106866736-A | A kind of central chirality-axial chirality electron deficient biphosphine ligand and its synthesis and application | 中国科学院大连化学物理研究所 | 2017-06-20 | — | — | CN | disclosed |
| WO-2016198836-A1 | ASYMMETRIC ADDITION REACTIONS | ISIS INNOVATION LIMITED (GB) | 2016-12-15 | — | — | WO | disclosed |
| US-9487494-B2 | Cyclic hydrocarbon compounds for the treatment of diseases | LEO PHARMA A/S (DK) | 2016-11-08 | — | — | US | disclosed |
| EP-2576538-B1 | New CCR2 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2015-10-28 | — | — | EP | disclosed |
| EP-2234961-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-10-06 | — | — | EP | disclosed |
| WO-2010070032-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-24 | — | — | WO | disclosed |
| US-20100022800-A1 | POLYMER HAVING BIS(DIPHENYLPHOSPHINO)BINAPHTHYL GROUPS | KYOEISHA CHEMICAL CO., LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| US-20100022800-A1 | POLYMER HAVING BIS(DIPHENYLPHOSPHINO)BINAPHTHYL GROUPS | KYOEISHA CHEMICAL CO., LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| WO-2009065406-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2009-05-28 | — | — | WO | disclosed |
| EP-2050776-A1 | POLYMER HAVING BIS(DIPHENYLPHOSPHINO)BINAPHTHYL GROUP | Kyoeisha Chemical Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
| EP-2050776-A1 | POLYMER HAVING BIS(DIPHENYLPHOSPHINO)BINAPHTHYL GROUP | Kyoeisha Chemical Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
| US-20050288523-A1 | Chiral diphosphorus compounds and transition metal complexes thereof | LANXESS DEUTSCHLAND GMBH (DE) | 2005-12-29 | — | — | US | disclosed |
| EP-1595885-A2 | Chiral diphosphorus compounds and their transition metal complexes | Lanxess Deutschland GmbH (DE) | 2005-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | MAPT 4609/4885GAA 4503/4885ESR2 776/4885 |
| US-20170173572-A1 | CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS | POF1B, FGFR1, COASY | MAPT 4198/4885GAA 3381/4885ESR2 1433/4885 |
| US-10464861-B2 | Asymmetric addition reactions | CSPP1, CCRL2, CBR3 | MAPT 3341/4885GAA 2737/4885ESR2 2844/4885 |
| US-20100022800-A1 | POLYMER HAVING BIS(DIPHENYLPHOSPHINO)BINAPHTHYL GROUPS | PCBP1, PARG, PHOSPHO1 | MAPT 2569/4885GAA 2906/4885ESR2 3797/4885 |
| US-10118169-B2 | Chiral ligand-based metal-organic frameworks for broad-scope asymmetric catalysis | POF1B, FGFR1, COASY | MAPT 4198/4885GAA 3381/4885ESR2 1433/4885 |
| US-20050288523-A1 | Chiral diphosphorus compounds and transition metal complexes thereof | PIN1, CDIPT, DDT | MAPT 2785/4885GAA 3504/4885ESR2 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.